Oncopeptides Chief Financial Officer Henrik Bergentoft takes office today

Oncopeptides AB, a biotech company focused on difficult to treat cancers, today announces that Henrik Bergentoft today takes office as the company´s new Chief Financial Officer

“I am happy to welcome Henrik who, with his robust experience and personal qualities will constitute a major asset for Oncopeptides and its leadership,” says Sofia Heigis, CEO of Oncopeptides.

“His more than 20 years of experience from leading finance roles at both medical and non-medical listed companies will be beneficial for us as we continue to build an organisation designed for growth.”

You may also like

Research & Development

Brainomix receives FDA clearance of e-Lung AI software

The software allows healthcare professionals to assess the condition of a patient with interstitial lung disease using AI technology
Manufacturing

Sartorius collaborate with NVIDIA to advance manufacturing with AI

The collaboration will aim to enhance research and development, as well as manufacturing protocols using artificial intelligence (AI)
Research & Development

Closed Loop Medicine & Pharmanovia's OptiZest study for precision hypertension therapeutic commences

The study will investigate the efficacy of at-home, personalised dose management with Zestril for the treatment of hypertension
Research & Development

LIfT BioSciences receives Innovate UK grant to accelerate IMAN cell therapy product development

In vivo studies will be conducted to determine the impact of IMAN cell therapies in solid tumour and immunology models developed by the Saeb-Parsy Lab at the University of Cambridge
Research & Development

Oxford BioDynamics and King’s College London collaborate to develop EpiSwitch biomarkers for rheumatoid arthritis

Prognostic and predictive biomarkers determined by EpiSwitch technology will allow for best prevention of rheumatoid arthritis following the APIPPRA trial
Research & Development

NeuroSense and PhaseV partner to optimise ALS Phase III trial using causal machine learning

PhaseV's causal machine learning predicts high probability of success in multiple ALS subgroups for NeuroSense's Phase II trial
Research & Development

BenevolentAI and AstraZeneca collaboration finds novel heart failure target

The heart failure target was discovered through an AI platform, with AstraZeneca then experimentally validating its clinical potential
Subscribe now